The development of novel immunotherapy utilizing iPS-cell derived myeloid lines against malignant melanoma

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09772
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Kumamoto University
• Principal Investigator: FUKUSHIMA SATOSHI 熊本大学, 大学院生命科学研究部(医), 准教授 (50398210)
• Co-Investigator(Renkei-kenkyūsha): IHN HIRONOBU 熊本大学, 大学院生命科学研究部, 教授 (20282634) ; JINNIN MASATOSHI 和歌山県立医科大学, 医学部, 教授 (60401048)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: がん免疫療法 / 悪性黒色腫 / iPS細胞 / マクロファージ / インターフェロン / IL-15 / NK細胞 / サイトカイン

Outline of Final Research Achievements

We have established iPS-cell derived myeloid cell lines. iPS-cell derived macrophages (iPS-MP) can be differentiated from them. The efficacy of iPS-MP against mouse melanoma was analyzed. We used the mice, tumor and iPS cells from same genetic background. The mice was C57BL6, so the mice has normal immune system. We observed the same efficacy of IFN-βintroduced iPS-MP as immunodeficiency mice. Furthermore, we established IL-15 introduced iPS-MP(iPS-MP-IL=15). iPS-MP-IL=15 showed the synergic effect upon the iPS-MP-IFN-β.

Free Research Field

がん免疫療法